Finding. Rotenone does not just starve Complex I. In SH-SY5Y cells pushed into a dopaminergic-neuron state, Complex I blockade raises reactive oxygen species, kills cells, and rearranges iron. Mitochondria and the whole cell gain iron. Cytosolic labile iron falls. Kill the ROS and the iron stops moving. Chelate the iron and the ROS stop climbing. Abdelrazeq Hassan, Grillo and colleagues put a loop, not a coincidence, between two Parkinson disease signatures.
Why this paper matters
Parkinson disease research has lived for years with two overlapping facts: substantia nigra neurons run hot on iron, and Complex I is fragile in the same cells, whether from genetics or from pesticides such as rotenone. The usual sentence is “both contribute to cytotoxicity.” That sentence does not say which way the arrow points.
Here the arrow is ROS first. Complex I inhibition is sufficient to break iron homeostasis. Antioxidants block both the oxidants and the iron pile-up, so the metal is not wandering in by a ROS-independent route in this system. Then the loop closes: iron chelation cuts further ROS, which is what you expect if mis-placed iron is Fenton fuel and not a side-effect.
Where the iron goes
The redistribution is the useful detail. Total and mitochondrial iron rise while cytosolic labile iron drops. That is retention and/or import into the organelle, not a simple whole-cell overload. The authors note that the mitochondrial [4Fe-4S] proteins they looked at took more damage than the [2Fe-2S] set. A damaged Fe-S scaffold that still holds iron is one way to trap metal in mitochondria and keep the oxidant cycle running.
They are careful about scope. The same logic, they say, may matter for sporadic Parkinson disease and for mitochondrial diseases that accumulate iron, Leigh syndrome named among them. That is a hypothesis list, not a patient cohort.
How to read the score
High eighties. Environmental Complex I poison, dopaminergic neurons, a bidirectional ROS–iron loop, and a cluster-type clue. Confidence is medium because the chassis is SH-SY5Y and the abstract does not name the transporter. Heuristic copy would have said “iron and ROS are both bad in Parkinson.” The paper says ROS from Complex I inhibition moves the iron, and the iron then pays ROS back.
Caveats
Rotenone in a dish is not a Braak stage. Labile-iron probes report pools, not every ferritin or mitoferrin molecule. [4Fe-4S] sensitivity is a slice of the Fe-S proteome. Nobody should start or stop chelation or antioxidant trials from this brief.
What to do with it
If you score Parkinson or Complex I papers, upgrade “iron dyshomeostasis” from a comorbidity tag to a ROS-dependent mitochondrial retention phenotype. If you build screens, the paired rescue (antioxidant versus chelator) is the experiment to clone. If you work on Leigh or other iron-loading OXPHOS diseases, this is a mechanistic analogy, not evidence those patients share the same transporter.